Arctic Bioscience AS (DE:9TD) has released an update.
Arctic Bioscience AS has presented new research at the ‘9th European Workshop on Lipid Mediators’ demonstrating the anti-inflammatory effects of their drug candidate, HRO350, derived from herring roe oil, on immune cells. This breakthrough suggests potential for treating psoriasis and other inflammatory diseases, with the HeROPA study’s results expected in late 2024. The company, known for developing pharmaceuticals and dietary supplements from bioactive marine materials, is at the forefront of lipidomics research and has conducted this project in Norway with significant contributions from national researchers.
For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.
